查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2084946

自體免疫疾病治療市場：2026-2032年全球市場預測（依藥物類別、作用機制、給藥途徑、適應症、最終用戶及通路分類）

Autoimmune Disease Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，自體免疫疾病治療市場規模將成長至 2,221.9 億美元，複合年成長率為 8.45%。

主要市場統計數據
基準年 2025 1258.6億美元
預計年份：2026年 1356.4億美元
預測年份 2032 2221.9億美元
複合年成長率 (%) 8.45%

自體免疫疾病治療市場主要由慢性免疫介導疾病所驅動，例如類風濕性關節炎、乾癬、乾癬性關節炎、發炎性腸道疾病、多發性硬化症、全身性紅斑性狼瘡、第一型糖尿病和自體免疫甲狀腺疾病。醫學文獻中已確認的自體免疫疾病超過80種，其中許多需要長期藥物治療，因此對免疫抑制劑、皮質類固醇、傳統緩解疾病抗風濕藥物（DMARDs）、生物製藥、生物相似藥和定向小分子藥物的需求持續存在。

市場發展勢頭主要受早期診斷、專科醫生診療管道增多、標靶治療方案的日益普及以及細胞激素抑制、B細胞調節、T細胞路徑、補體抑制、 Janus激酶抑制、鞘氨醇-1-磷酸受體調節和新興的布魯頓蛋白酪氨酸激酶抑製劑等領域的持續創新所驅動。同時，來自保險公司的壓力、生物相似藥的競爭、安全性監測以及真實世界數據（REW）的要求正在重新定義自體免疫疾病療法的研發、定價、處方和報銷。

自體免疫疾病治療領域發生的變革性變化

自體免疫疾病的治療方法正從廣泛的免疫抑制轉向精準免疫學，越來越多的治療方案選擇基於疾病表現型、生物標記物譜、既往治療反應、合併症風險以及首選給藥途徑。雖然生物製劑在高價值自體免疫疾病治療中仍發揮核心作用，但生物相似藥正在重塑腫瘤壞死因子抑制劑和其他單株抗體等成熟領域的競爭格局。

人工智慧（AI）的累積影響

人工智慧（AI）正在自體免疫疾病的藥物發現、臨床開發、商業化和藥物安全性監測的各個階段創造累積價值。 AI驅動的分析能夠識別免疫通路標靶、分析基因組和蛋白質組資料集以及構建疾病進展模型，從而支持對全身性紅斑性狼瘡、發炎性腸道疾病、銀屑病、類風濕性關節炎和多發性硬化症等高度異質性疾病進行患者分層。

對關鍵區域的洞察

北美憑藉其強大的專業醫療基礎設施、先進的生物製藥、FDA創新核准途徑以及廣泛的臨床試驗活動，仍然是自體免疫疾病治療領域的領先地區。該地區的大部分需求來自美國，而加拿大則專注於系統性的報銷審查。歐洲則擁有高診斷率、EMA（歐洲藥品管理局）的監管、完善的臨床指南以及成熟的醫療技術評估系統。同時，在歐盟主要市場和英國，從成本控制的角度來看，生物相似藥的引入尤其重要。

對關鍵群體的洞察

七國集團（G7）憑藉先進的研究生態系統、經驗豐富的監管機構、健全的藥物安全監測體系和大規模的專科藥物市場，持續推動高價值自體免疫疾病治療領域的創新。歐盟在生物相似藥政策、集中核准、衛生技術評估協調、真實世界數據（REW）標準以及跨境藥物安全監測方面發揮核心作用，從而支持其成員國的創新和成本效益。

主要國家的概況

美國在自體免疫疾病治療領域擁有最大的商業機遇，這得益於專科醫生的處方、生物製藥的普及、新療法的快速應用、臨床試驗的積極參與以及大量商業性世界證據的積累。另一方面，加拿大則強調循證報銷、藥物動力學評估以及將藥物納入省級處方藥目錄。墨西哥和巴西正在擴展自體免疫疾病治療體系，但仍對成本效益、公共採購、生物相似藥的可及性以及專科治療的連續性保持關注。在歐洲，英國、德國、法國、義大利和西班牙將高臨床標準與嚴格的定價和藥物動力學評估結合。然而，由於報銷範圍、當地供應趨勢和監管條件的不同，俄羅斯的藥物可及性存在差異。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的作用機制、檢驗的生物標記以及患者細分策略，以期在現有生物製藥和傳統疾病修正治療的基礎上，進一步改善治療效果。在成熟領域競爭的企業需要製定充分考慮生物相似藥的生命週期規劃，其中包括醫療設備創新、用藥依從性支持、真實世界數據 (REW) 收集，以及針對一線療法無效、復發或不耐受患者的明確定位。

調查方法

本執行摘要基於結構化的研究方法，全面交叉引用了法規核准、臨床試驗註冊數據、同行評審文獻、衛生技術評估 (HTA) 結果、公共衛生資訊來源、治療指南、藥物警戒更新和市場進入資訊。常用的調查方法資訊來源包括美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、各國監管機構、ClinicalTrials.gov、世界衛生組織 (WHO) 相關公共衛生數據、經合組織 (OECD) 健康指標以及風濕病學、皮膚病學、神經病學、內分泌學和胃腸病學領域的關鍵指南。

結論

自體免疫疾病治療市場競爭日益激烈，且更主導。這一階段不僅要求科學創新，還要求藥物的可近性、安全性、可負擔性和真實世界的臨床療效。生物製藥和標靶小分子藥物不斷改善免疫介導疾病的治療效果，而生物相似藥、醫療技術評估的嚴格審查以及保險公司的監管也將重塑定價、報銷和治療順序。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：自體免疫疾病治療市場：依藥物類別分類

  • 生物製劑
    • 融合蛋白
    • 單株抗體
    • 胜肽
  • 生物相似藥
  • 低分子化合物

第8章：自體免疫疾病治療藥物市場：依作用機制分類

  • B細胞清除劑
  • IL抑制劑
    • IL-17抑制劑
    • IL-23抑制劑
    • IL-6抑制劑
  • JAK抑制劑
    • JAK1抑制劑
    • JAK1/2抑制劑
    • JAK3抑制劑
  • TNF抑制劑

第9章：自體免疫疾病治療市場：依給藥途徑分類

  • 口服
    • 膠囊
    • 解決方案
    • 藥片
  • 腸外
    • 靜脈
    • 皮下

第10章：自體免疫疾病治療市場：依適應症分類

  • 發炎性腸道疾病
    • 克隆氏症
    • 潰瘍性大腸炎
  • 狼瘡
  • 多發性硬化症
  • 銀屑病
    • 斑塊型乾癬
    • 乾癬性關節炎
  • 類風濕性關節炎

第11章：自體免疫疾病治療市場：依最終用戶分類

  • 診所
  • 居家照護環境
  • 醫院

第12章：自體免疫疾病治療市場：依通路分類

  • 離線
  • 線上

第13章：自體免疫疾病治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：自體免疫疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：自體免疫疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • Biocon Limited
  • Bioton SA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Eva Pharma
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Gulf Pharmaceutical Industries（Julphar）
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co., Inc.
  • MJ Biopharm Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-436901065FE5

The Autoimmune Disease Drugs Market is projected to grow by USD 222.19 billion at a CAGR of 8.45% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 125.86 billion
Estimated Year [2026] USD 135.64 billion
Forecast Year [2032] USD 222.19 billion
CAGR (%) 8.45%

The autoimmune disease drugs market is anchored by chronic, immune-mediated conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, and autoimmune thyroid disorders. More than 80 autoimmune diseases are recognized in medical literature, and many require long-term pharmacologic management, creating sustained demand for immunosuppressants, corticosteroids, conventional disease-modifying antirheumatic drugs, biologics, biosimilars, and targeted small molecules.

Market momentum is being shaped by earlier diagnosis, expanding specialist access, rising use of treat-to-target protocols, and continued innovation in cytokine inhibition, B-cell modulation, T-cell pathways, complement inhibition, Janus kinase inhibition, sphingosine-1-phosphate receptor modulation, and emerging Bruton tyrosine kinase inhibitors. At the same time, payer pressure, biosimilar competition, safety monitoring, and real-world evidence requirements are redefining how autoimmune disease drugs are developed, priced, prescribed, and reimbursed.

Transformative Shifts in the Autoimmune Treatment Landscape

The autoimmune treatment landscape is moving from broad immune suppression toward precision immunology, where therapies are increasingly selected according to disease phenotype, biomarker profile, prior treatment response, comorbidity risk, and route-of-administration preference. Biologics remain central in high-value autoimmune therapy categories, while biosimilars are reshaping competition in established segments such as tumor necrosis factor inhibitors and other monoclonal antibody classes.

Transformative shifts include stronger adoption of self-injectable and oral targeted therapies, growing post-marketing safety oversight for JAK inhibitors and other immunomodulators, and rising payer demand for comparative effectiveness evidence. Manufacturers are also adapting to decentralized clinical trials, patient support programs, specialty pharmacy models, and value-based contracting, all of which influence market access, adherence, and brand durability.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across autoimmune disease drug discovery, clinical development, commercialization, and pharmacovigilance. AI-enabled analytics can identify immune pathway targets, mine genomic and proteomic datasets, model disease progression, and support patient stratification in heterogeneous conditions such as systemic lupus erythematosus, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and multiple sclerosis.

The strongest impact is emerging where AI improves trial feasibility, enriches responder populations, accelerates safety signal detection, and converts real-world data into actionable evidence for regulators, payers, clinicians, and patients. Responsible adoption requires transparent models, bias assessment, data privacy controls, and clinical validation, particularly because autoimmune diseases disproportionately affect women and often present with variable symptoms across ancestry groups, age cohorts, and care settings.

Key Regional Insights

North America remains a leading region for autoimmune disease drugs due to strong specialty care infrastructure, advanced biologic use, FDA innovation pathways, and broad clinical trial activity, with the United States driving most regional demand and Canada emphasizing structured reimbursement review. Europe combines high diagnosis rates, EMA oversight, established clinical guidelines, and mature health technology assessment systems, while biosimilar adoption is particularly important in cost containment across major European Union markets and the United Kingdom.

Asia-Pacific is expanding rapidly as China, Japan, India, South Korea, and Australia invest in biologics, biosimilars, local manufacturing, clinical research capacity, and broader access to specialty medicines. Latin America, led by Brazil and Mexico, is improving access through public procurement and private insurance channels, although affordability, reimbursement consistency, and specialist availability remain constraints. The Middle East, especially GCC markets, is increasing biologic uptake through hospital modernization, national health strategies, and specialty care investment, while Africa continues to face access gaps linked to diagnostic capacity, rheumatology and immunology specialist shortages, cold-chain limitations, and reimbursement constraints.

Key Group Insights

The G7 continues to anchor high-value autoimmune drug innovation through advanced research ecosystems, experienced regulatory agencies, strong pharmacovigilance systems, and large specialty pharmaceutical markets. The European Union plays a central role in biosimilar policy, centralized approvals, health technology assessment alignment, real-world evidence standards, and cross-border pharmacovigilance, supporting both innovation and cost efficiency across member states.

BRICS countries are increasingly important for patient access expansion, local biologics production, biosimilar development, and clinical trial diversification, with China, India, and Brazil standing out for scale and manufacturing capacity. ASEAN markets are progressing through broader healthcare coverage, improving diagnostic pathways, and better specialist access, although reimbursement depth varies widely across member countries. GCC countries are investing in premium care infrastructure, digital health, biologic access, and centralized procurement capabilities, while NATO is not a healthcare market bloc but includes countries prioritizing medicine supply resilience, procurement security, emergency preparedness, and biopharmaceutical manufacturing continuity.

Key Country Insights

The United States is the largest commercial opportunity within autoimmune disease drugs, supported by specialist prescribing, biologic penetration, rapid uptake of novel therapies, robust clinical trial participation, and extensive real-world evidence generation, while Canada emphasizes evidence-based reimbursement, health technology review, and provincial formulary access. Mexico and Brazil are expanding autoimmune treatment capacity but remain sensitive to affordability, public procurement, biosimilar availability, and continuity of specialty care. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical standards with strict pricing and health technology assessment scrutiny, while Russia presents access variability tied to reimbursement coverage, local supply dynamics, and regulatory conditions.

China is accelerating biologics and biosimilars through regulatory reform, domestic innovation, and broader hospital access, while India is a major growth market for cost-effective therapies, biosimilars, and local manufacturing. Japan remains a sophisticated market with strong specialty care, high regulatory standards, and an aging population that influences autoimmune and inflammatory disease management. Australia benefits from structured public reimbursement and evidence-based access pathways, and South Korea combines advanced healthcare infrastructure with competitive biosimilar development, high digital health adoption, and export-oriented biopharmaceutical capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated mechanisms of action, validated biomarkers, and patient segmentation strategies that improve outcomes beyond established biologics and conventional disease-modifying therapies. Organizations competing in mature categories need biosimilar-aware lifecycle planning, including device innovation, adherence support, real-world evidence generation, and clear positioning for patients who fail, relapse on, or cannot tolerate first-line therapies.

Commercial success will depend on early payer engagement, robust pharmacoeconomic evidence, scalable patient assistance programs, and region-specific access strategies aligned with local reimbursement rules and clinical practice patterns. Leaders should also invest in AI governance, diverse clinical trial recruitment, supply chain resilience, cold-chain reliability, and post-marketing surveillance to strengthen trust with regulators, clinicians, payers, and patients.

Research Methodology

This executive summary is developed through a structured research methodology that triangulates regulatory approvals, clinical trial registries, peer-reviewed literature, health technology assessment outputs, public health sources, treatment guidelines, pharmacovigilance updates, and market access intelligence. Sources commonly assessed include the FDA, EMA, national regulatory agencies, ClinicalTrials.gov, WHO-linked public health data, OECD health indicators, and leading rheumatology, dermatology, neurology, endocrinology, and gastroenterology guidance.

The analysis evaluates therapy class dynamics, disease-area demand signals, regional access conditions, competitive positioning, pricing pressure, pipeline maturity, biosimilar penetration, regulatory developments, safety trends, and evidence-generation requirements. Findings are synthesized to identify durable market drivers, constraints, and strategic implications for stakeholders across the autoimmune disease drugs value chain, while avoiding unsupported market sizing or forecasting assumptions.

Conclusion

The autoimmune disease drugs market is entering a more competitive and evidence-driven phase, where scientific innovation must be matched by access, safety, affordability, and real-world performance. Biologics and targeted small molecules will continue to transform outcomes across immune-mediated disorders, while biosimilars, health technology assessment scrutiny, and payer controls will reshape pricing, reimbursement, and treatment sequencing.

Organizations that combine precision immunology, AI-enabled development, strong pharmacovigilance, differentiated delivery formats, and localized market access strategies will be best positioned to strengthen performance. The most durable opportunities will emerge in therapies that demonstrate sustained disease control, improved quality of life, convenient administration, safety confidence, and measurable value across diverse healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Autoimmune Disease Drugs Market, by Drug Class

  • 7.1. Biologics
    • 7.1.1. Fusion Proteins
    • 7.1.2. Monoclonal Antibodies
    • 7.1.3. Peptides
  • 7.2. Biosimilars
  • 7.3. Small Molecules

8. Autoimmune Disease Drugs Market, by Mechanism Of Action

  • 8.1. B Cell Depleting Agents
  • 8.2. Il Inhibitors
    • 8.2.1. Il17 Inhibitors
    • 8.2.2. Il23 Inhibitors
    • 8.2.3. Il6 Inhibitors
  • 8.3. Jak Inhibitors
    • 8.3.1. Jak1 Inhibitors
    • 8.3.2. Jak1/2 Inhibitors
    • 8.3.3. Jak3 Inhibitors
  • 8.4. Tnf Inhibitors

9. Autoimmune Disease Drugs Market, by Route Of Administration

  • 9.1. Oral
    • 9.1.1. Capsule
    • 9.1.2. Solution
    • 9.1.3. Tablet
  • 9.2. Parenteral
    • 9.2.1. Intravenous
    • 9.2.2. Subcutaneous

10. Autoimmune Disease Drugs Market, by Indication

  • 10.1. Inflammatory Bowel Disease
    • 10.1.1. Crohn's Disease
    • 10.1.2. Ulcerative Colitis
  • 10.2. Lupus
  • 10.3. Multiple Sclerosis
  • 10.4. Psoriasis
    • 10.4.1. Plaque Psoriasis
    • 10.4.2. Psoriatic Arthritis
  • 10.5. Rheumatoid Arthritis

11. Autoimmune Disease Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare Settings
  • 11.3. Hospitals

12. Autoimmune Disease Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Autoimmune Disease Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Autoimmune Disease Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Autoimmune Disease Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Astellas Pharma Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. Baxter International, Inc.
  • 17.5. Bayer AG
  • 17.6. Biocon Limited
  • 17.7. Bioton S.A.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Eli Lilly and Company
  • 17.11. Eva Pharma
  • 17.12. GlaxoSmithKline PLC
  • 17.13. Glenmark Pharmaceuticals Limited
  • 17.14. Gulf Pharmaceutical Industries (Julphar)
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. Lupin Limited
  • 17.17. MannKind Corporation
  • 17.18. Merck & Co., Inc.
  • 17.19. MJ Biopharm Pvt. Ltd.
  • 17.20. Novartis AG
  • 17.21. Novo Nordisk A/S
  • 17.22. Oramed Pharmaceuticals Inc.
  • 17.23. Pfizer Inc.
  • 17.24. Sanofi S.A.
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 17.27. Viatris Inc.
  • 17.28. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FUSION PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL B CELL DEPLETING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL B CELL DEPLETING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL B CELL DEPLETING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IL INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IL INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IL INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IL17 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IL17 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IL17 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IL23 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IL23 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IL23 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IL6 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IL6 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IL6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL JAK1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL JAK1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL JAK1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL JAK1/2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL JAK1/2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL JAK1/2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL JAK3 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL JAK3 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL JAK3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CROHN'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CROHN'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CROHN'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LUPUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LUPUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LUPUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 223. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 227. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 228. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 265. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 266. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 269. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 270. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 279. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 283. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 284. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 287. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 307. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 320. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 321. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 332. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 334. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 335. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 336. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 337. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 338. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 340. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 341. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 342. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 343. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 344. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 345. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 352. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED KINGDOM AUTOIMMU